利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.027 秒)

    Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling
    1.
    发明授权
    Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling 有权
    体外离体和体外修复和再生软骨和胶原和骨重塑的方法

    公开(公告)号：US06528052B1

    公开(公告)日：2003-03-04

    申请号：US09677109

    申请日：2000-09-29

    申请人： R. Lane Smith ,  Dennis R. Carter ,  David J. Schurman

    发明人： R. Lane Smith ,  Dennis R. Carter ,  David J. Schurman

    IPC分类号： C12N500

    CPC分类号： C12N5/0655 ,  A61F2/08 ,  A61F2/28 ,  A61F2/30756 ,  A61F2/3094 ,  A61F2240/001 ,  A61F2310/00365 ,  A61K35/12 ,  A61K35/32 ,  C12N2500/02 ,  C12N2521/00

    摘要： A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied hydrostatic pressure followed and interrupted by periods of recovery. The application of the intermittent hydrostatic pressure at physiological levels 5-10 MPA for an interval of 4 hours followed by a recovery period up to about 20 hours, said pressure applied to the cartilage cells in vitro, explants of cartilage ex vivo and in vivo to cartilage that remains intact within te joint space of diarthrotic joints. The interval loading results in the selective inhibition of matrix degrading enzymes, pro-inflammatory cytokines and chemokines that attract inflammatory cells into the joint cavity and in selective decrease of gene, expression of growth factors that are inhibitory to type II collagen expression.

    摘要翻译： 一种体内，体外和体外再生软骨和胶原蛋白的方法。 通过间歇施加的静水压力，体内，离体和体外再生和从头形成关节软骨和胶原。 外部间隔负荷的应用由反复施加的静水压力组成，随后由复原期间中断。 在生理水平5-10MPA下间歇4小时的间歇静水压力的应用，随后的恢复期直到约20小时，所述压力在体外施加于软骨细胞，体外离体外植体和体内至软体 在关节关节的关节间隙内保持完整的软骨。 间隔负荷导致基质降解酶，促炎细胞因子和趋化因子的选择性抑制，其吸引炎症细胞进入关节腔，并选择性降低基因，抑制II型胶原表达的生长因子的表达。

    Method for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling
    2.
    发明申请
    Method for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling 审中-公开
    体内，体外和体外修复和再生软骨和胶原蛋白和骨重塑的方法

    公开(公告)号：US20090176304A1

    公开(公告)日：2009-07-09

    申请号：US11980967

    申请日：2008-07-11

    申请人： R. Lane Smith ,  Dennis R. Carter ,  David J. Schurman

    发明人： R. Lane Smith ,  Dennis R. Carter ,  David J. Schurman

    IPC分类号： C12N5/08 ,  C12N5/06

    CPC分类号： C12N5/0655 ,  A61F2/08 ,  A61F2/28 ,  A61F2/30756 ,  A61F2/3094 ,  A61F2240/001 ,  A61F2310/00365 ,  A61K35/12 ,  A61K35/32 ,  C12N2500/02 ,  C12N2521/00

    摘要： A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied hydrostatic pressure followed and interrupted by periods of recovery. The application of the intermittent hydrostatic pressure at physiological levels 5-10 MPA for an interval of 4 hours followed by a recovery period up to about 20 hours, said pressure applied to the cartilage cells in vitro, explants of cartilage ex vivo and in vivo to cartilage that remains intact within te joint space of diarthrotic joints. The interval loading results in the selective inhibition of matrix degrading enzymes, pro-inflammatory cytokines and chemokines that attract inflammatory cells into the joint cavity and in selective decrease of gene expression of growth factors that are inhibitory to type II collagen expression.

    摘要翻译： 一种体内，体外和体外再生软骨和胶原蛋白的方法。 通过间歇施加的静水压力，体内，离体和体外再生和从头形成关节软骨和胶原。 外部间隔负荷的应用由反复施加的静水压力组成，随后由复原期间中断。 在生理水平5-10MPA下间歇4小时的间歇静水压力的应用，随后的恢复期直到约20小时，所述压力在体外施加于软骨细胞，体外离体外植体和体内至软体 在关节关节的关节间隙内保持完整的软骨。 间隔负荷导致基质降解酶，促炎细胞因子和趋化因子的选择性抑制，其吸引炎症细胞进入关节腔，并选择性降低抑制II型胶原表达的生长因子的基因表达。

    TISSUE ENGINEERING USING PROGENITOR CELLS TO CATALYZE TISSUE FORMATION BY PRIMARY CELLS
    3.
    发明申请
    TISSUE ENGINEERING USING PROGENITOR CELLS TO CATALYZE TISSUE FORMATION BY PRIMARY CELLS 审中-公开
    组织工程使用原核细胞催化原代细胞组织形成

    公开(公告)号：US20140219972A1

    公开(公告)日：2014-08-07

    申请号：US14173628

    申请日：2014-02-05

    申请人： Janice Lai ,  William Maloney ,  R. Lane Smith ,  Fan Yang

    发明人： Janice Lai ,  William Maloney ,  R. Lane Smith ,  Fan Yang

    IPC分类号： A61K35/12 ,  A61K35/32

    CPC分类号： A61K35/35 ,  A61K35/28 ,  A61K35/32 ,  A61K35/34 ,  A61K35/51 ,  A61K35/545

    摘要： Methods of regenerating tissue using progenitor cells in combination with primary cells from a target tissue are disclosed. In particular, progenitor cells catalyze proliferation and tissue production by primary cells allowing the use of fewer primary cells from a target tissue for effective tissue regeneration. Cell-based therapies combining progenitor cells and primary cells can be used for repair and regeneration of damaged tissue and organs for treating bodily injuries and degenerative diseases. For example, adipose-derived stem cells and neonatal articular chondrocytes, co-encapsulated in mixed or bilayered cultures in a hydrogel comprising chondroitin sulfate methacrylate and poly(ethylene)glycol diacrylate, generated cartilage that could be used for treatment of traumatic injuries or diseases involving cartilage degeneration. Moreover, the inventors showed that progenitor cells could be used to stimulate cartilage formation with a minimal number of primary cells, as few as 1% or less, in mixed cultures containing primary cells and progenitor cells.

    摘要翻译： 公开了使用祖细胞与来自靶组织的原代细胞组合再生组织的方法。 特别地，祖细胞催化原代细胞的增殖和组织产生，从而允许使用较少的来自靶组织的原代细胞用于有效的组织再生。 结合祖细胞和原代细胞的基于细胞的疗法可用于损伤组织和器官的修复和再生，用于治疗身体损伤和退行性疾病。 例如，由包含硫酸软骨素甲基丙烯酸酯和聚（乙二醇）二丙烯酸酯的水凝胶共混包封在混合或双层培养物中的脂肪来源的干细胞和新生儿关节软骨细胞产生的软骨可用于治疗创伤性损伤或涉及 软骨变性。 此外，发明人显示，在含有原代细胞和祖细胞的混合培养物中，祖细胞可用于刺激在最少数量的原代细胞中形成软骨，少至1％或更少。

    Thyroid-derived chondrocyte-stimulating factor
    5.
    发明授权
    Thyroid-derived chondrocyte-stimulating factor 失效
    甲状腺来源的软骨细胞刺激因子

    公开(公告)号：US5284830A

    公开(公告)日：1994-02-08

    申请号：US654965

    申请日：1991-02-13

    申请人： R. Lane Smith ,  Deryk G. Jones

    发明人： R. Lane Smith ,  Deryk G. Jones

    IPC分类号： A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61K47/48 ,  A61L27/22 ,  A61P43/00 ,  C07K1/16 ,  C07K1/30 ,  C07K14/435 ,  C07K14/51 ,  C07K14/705 ,  C07K16/00 ,  C07K16/22 ,  C12N5/06 ,  C12P21/08 ,  G01N33/53 ,  A61K37/36 ,  C07K3/02 ,  C07K15/06

    CPC分类号： A61K47/48238 ,  A61L27/227 ,  C07K14/51 ,  C07K16/22 ,  A61K38/00 ,  Y10S530/854

    摘要： Thyroid-derived chondrocyte stimulating factor (TDCSF) is a high molecular weight complex (greater than 500 kd) of proteinaceous subunits which can be at least partially dissociated into active portions by 8 M urea. TDCSF stimulates articular chondrocyte and synovial fibroblast growth under serum-free conditions. TDCSF is useful for the culture of chondrocytes and fibroblasts in vitro as a serum substitute; for developing cartilage implants in vitro; and for in vivo use in cartilage and bone defect repair and degenerative joint diseases. TDCSF is stabilized in the presence of reducing agents for disulfide bonds. Antibodies for and conjugates of TDCSF are also disclosed.

    摘要翻译： 甲状腺来源的软骨细胞刺激因子（TDCSF）是蛋白质亚基的高分子量复合物（大于500kd），其可以通过8M尿素至少部分地分解为活性部分。 TDCSF在无血清条件下刺激关节软骨细胞和滑膜成纤维细胞生长。 TDCSF可用于体外培养软骨细胞和成纤维细胞作为血清替代物; 用于在体外开发软骨植入物; 并用于体内用于软骨和骨缺损修复和退行性关节疾病。 TDCSF在二硫键还原剂存在下稳定。 还公开了TDCSF的抗体和缀合物。

    Thyroid-derived chondrocyte-stimulating factor
    8.
    发明授权
    Thyroid-derived chondrocyte-stimulating factor 失效
    甲状腺来源的软骨细胞刺激因子

    公开(公告)号：US5374550A

    公开(公告)日：1994-12-20

    申请号：US152224

    申请日：1993-11-12

    申请人： R. Lane Smith ,  Deryk G. Jones

    发明人： R. Lane Smith ,  Deryk G. Jones

    IPC分类号： A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61K47/48 ,  A61L27/22 ,  A61P43/00 ,  C07K1/16 ,  C07K1/30 ,  C07K14/435 ,  C07K14/51 ,  C07K14/705 ,  C07K16/00 ,  C07K16/22 ,  C12N5/06 ,  C12P21/08 ,  G01N33/53 ,  A61F2/08 ,  C12N5/08

    CPC分类号： A61K47/48238 ,  A61L27/227 ,  C07K14/51 ,  C07K16/22 ,  A61K38/00 ,  Y10S530/854

    摘要： Thyroid-derived chondrocyte stimulating factor (TDCSF) is a high molecular weight complex (greater than 500 kd) of proteinaceous subunits which can be at least partially dissociated into active portions by 8M urea. TDCSF stimulates articular chondrocyte and synovial fibroblast growth under serum-free conditions. TDCSF is useful for the culture of chondrocytes and fibroblasts in vitro as a serum substitute; for developing cartilage implants in vitro; and for in vivo use in cartilage and bone defect repair and degenerative joint diseases. TDCSF is stabilized in the presence of reducing agents for disulfide bonds. Antibodies for and conjugates of TDCSF are also disclosed.

    摘要翻译： 甲状腺来源的软骨细胞刺激因子（TDCSF）是蛋白质亚基的高分子量复合物（大于500kd），其可以通过8M尿素至少部分地分解成活性部分。 TDCSF在无血清条件下刺激关节软骨细胞和滑膜成纤维细胞生长。 TDCSF可用于体外培养软骨细胞和成纤维细胞作为血清替代物; 用于在体外开发软骨植入物; 并用于体内用于软骨和骨缺损修复和退行性关节疾病。 TDCSF在二硫键还原剂存在下稳定。 还公开了TDCSF的抗体和缀合物。